1,579 Followers on Owler

Allogene

Therapeutics develops an allogeneic chimeric antigen receptor for the treatment of cancer... Read more
OverviewCompetitorsFundingInvestmentsNews & Insights

Allogene

Therapeutics develops an allogeneic chimeric antigen receptor for the treatment of cancer... Read more
Allogene President & CEO: David Chang

President & CEO

David Chang

CEO Approval Rating

65/100

2017

PublicNASDAQALLO

Pharmaceuticals & Biotechnology
Biotechnology
28342836 NAICS listing

Annual Revenue
$ < 1M
Employees
310
Funding
$834.8M
Investments
2

News

Partnership
Mar 03, 2025
BizWest
Foresight Diagnostics expands Allogene partnership
Conference Presentation
Feb 26, 2025
centralcharts
Allogene Therapeutics Announces Participation in March Investor Conference
Regulatory
Jan 29, 2025
Zacks
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases
Funding
May 01, 2024
finance.yahoo.com
Allogene received $15M in Grant Funding

Allogene Competitors

1Cellectis
2Mustang Bio
3bluebird bio
4Novartis
5Poseida
6Atara
7Kite Pharma
8CRISPR
9Bristol-Myers Squibb
10Nexo Therapeutics
Unlock 14 + competitors

Trending Companies